James Wild

Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain

James Wild, Stefan Grond, Brigitte Kuperwasser et al. · Pain Practice · 2010 · 181 citations

Efficacy and Safety of Controlled-Release Versus Immediate-Release Oxycodone: Randomized, Double-Blind Evaluation in Patients with Chronic Back Pain

M. Hale, Roy Fleischmann, Robert T. Salzman et al. · Clinical Journal of Pain · 1999 · 134 citations

Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials

M. Hale, James Wild, Jyotsna Reddy et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 124 citations

Opioid Epidemic, Parallel-group Trials, Phase 3 +12

Can a Controlled-Release Oral Dose Form of Oxycodone Be Used as Readily as an Immediate-Release Form for the Purpose of Titrating to Stable Pain Control?

Robert T. Salzman, Michael S. Roberts, James Wild et al. · Journal of Pain and Symptom Management · 1999 · 108 citations · Full text

Health Sciences, Pain Medicine, Stable Pain Control +10

Single-Entity Hydrocodone Extended-Release Capsules in Opioid-Tolerant Subjects with Moderate-to-Severe Chronic Low Back Pain: A Randomized Double-Blind, Placebo-Controlled Study

Richard Rauck, Srinivas Nalamachu, James Wild et al. · Pain Medicine · 2014 · 51 citations · Full text